REG - GlaxoSmithKline PLC - Director/PDMR Shareholding

GSKAnnouncement

16/04/2019 17:40

RNS Number : 4072W
GlaxoSmithKline PLC
16 April 2019
 


GlaxoSmithKline plc (the 'Company')
Transaction notification




1.


Details of PDMR/person closely associated with them ('PCA')


 




a)


Name


Ms E Walmsley


 




b)


Position/status


Chief Executive Officer


 




c)


Initial notification/
amendment


Initial notification


 




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor


 




a)


Name


GlaxoSmithKline plc


 




b)


LEI


5493000HZTVUYLO1D793


 




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted


 




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 


 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.


 




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


908.000




£15.6560


260.000




£15.6560


912.000




£15.6560


260.000




 
 
 


 




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
2340.000 
£15.6560
 


 




e)


Date of the transaction


2019-04-12

 


 




f)


Place of the transaction
 


London Stock Exchange (XLON)


 



 
 
 



 


1.


Details of PDMR/person closely associated with them ('PCA')




 


a)


Name


Dr H Barron




 


b)


Position/status


Chief Scientific Officer and President, R&D




 


c)


Initial notification/
amendment


Initial notification




 


2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




 


a)


Name


GlaxoSmithKline plc




 


b)


LEI


5493000HZTVUYLO1D793




 


3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




 


a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 




 


b)


Nature of the transaction


Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.




 


c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.9400


538.000




 
 
 




 


d)


Aggregated information
Aggregated volume Price


 
n/a (single transaction)
 
 
 
 




 


e)


Date of the transaction


2019-04-12




 


f)


Place of the transaction
 


New York Stock Exchange (XNYS)



 
 
 
 
 
 
 



 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R G Connor




b)


Position/status


President, Global Vaccines




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


238.000




£15.6560


135.000




£15.6560


193.000




£15.6560


135.000




 
 
 




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
701.000 
£15.6560
  




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr S P Dingemans




b)


Position/status


Executive Director




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


649.000




£15.6560


236.000




£15.6560


645.000




£15.6560


236.000




 
 
 




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
1766.000 
£15.6560
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr J Ford




b)


Position/status


SVP and General Counsel




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 




b)


Nature of the transaction


Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.9400


46.000




  
 




d)


Aggregated information
 
Aggregated volume Price


n/a (single transaction)
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr N Hirons




b)


Position/status


SVP, Global Ethics & Compliance




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


99.000




£15.6560


85.000




£15.6560


101.000




£15.6560


85.000




 
 
 




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
370.000 
£15.6560
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr B McNamara




b)


Position/status


CEO, GSK Consumer Healthcare




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 




b)


Nature of the transaction


Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.9400


90.000




$ 40.9400


98.000




$ 40.9400


96.000




 
 
 




d)


Aggregated information
 
Aggregated volume Price


 
 
 


284.000 
$ 40.9400




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr L Miels




b)


Position/status


President, Global Pharmaceuticals




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


253.000




£15.6560


183.000




 
  




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
436.000

£15.6560
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr D Redfern




b)


Position/status


Chief Strategy Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


225.000




£15.6560


107.000




£15.6560


187.000




£15.6560


107.000




  
 




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
626.000 
£15.6560
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr R Simard




b)


Position/status


President, Pharmaceuticals Supply Chain




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


81.000




 
 
 




d)


Aggregated information
 
Aggregated volume Price


 
n/a (single transaction)
 
 
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 
 
  




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Ms K Terrell




b)


Position/status


Chief Digital & Technology Officer




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


American Depositary Shares ('ADSs')
ISIN: US37733W1053 
 




b)


Nature of the transaction


Increase in interest in American Depository Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on American Depository Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




$ 40.9400


114.000




$ 40.9400


32.000




 
  




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
146.000
$ 40.9400
  




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


New York Stock Exchange (XNYS)




 
 
 
 




1.


Details of PDMR/person closely associated with them ('PCA')




a)


Name


Mr P C Thomson




b)


Position/status


President, Global Affairs




c)


Initial notification/
amendment


Initial notification




2.


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a)


Name


GlaxoSmithKline plc




b)


LEI


5493000HZTVUYLO1D793




3.


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted




a)


Description of the financial instrument


Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
 




b)


Nature of the transaction


Increase in interest in Ordinary Shares following the re-investment of dividends paid to shareholders on 11 April 2019 on Ordinary Shares held in the Company's Deferred Annual Bonus Plan.




c)


Price(s) and volume(s)






Price(s)


Volume(s)




£15.6560


131.000




£15.6560


102.000




£15.6560


126.000




 
  




d)


Aggregated information
 
Aggregated volume Price


 
 
 
 
359.000 
£15.6560
 




e)


Date of the transaction


2019-04-12




f)


Place of the transaction
 


London Stock Exchange (XLON)




 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQQLFFKZFXBBX